Deal Dispatch: Sage And Silvus Are Up For Sale, MrBeast Secures $20B For TikTok Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

In a report released today, Joon Lee from Truist Financial maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report). The ...

Sage Therapeutics Inc (SAGE) reports significant prescription growth for ZURZUVAE, despite a net loss and strategic ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...

H.C. Wainwright lowered the firm’s price target on Sage Therapeutics (SAGE) to $12 from $14 and keeps a Neutral rating on the shares. The ...

Shares of Sage Therapeutics jumped nearly 40% in premarket trading Monday after the biopharmaceutical company received an unsolicited buyout bid from partner Biogen. Biogen, which already owns a ...

Sage Therapeutics SAGE announced that its board of directors has rejected the unsolicited, non-binding proposal offer from drug giant Biogen BIIB to acquire the remaining shares of SAGE. Per Sage ...

Our calculations are based on comprehensive, delayed quotes. Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all ...

(RTTNews) - Shares of Sage Therapeutics Inc. (SAGE) jumped over 45% to $8.09 in after-hours on Friday, on receipt of an unsolicited, nonbinding acquisition proposal from Biogen Inc. (BIIB).